Skip to content
WorldBrand.AI
HomeAboutBrand WikiAEOWorld ModelComing SoonBlog
WorldBrand.AI

The intelligence platform for brands in the AI era.

Products
  • AEO Intelligence
  • Brand Wiki
  • World Model
  • Enterprise
Company
  • About
  • Blog
  • Pricing
Brand Wiki
  • About Brand Wiki
  • Methodology
  • Sources
  • Editorial policy
  • API

© 2026 WorldBrand.ai. All rights reserved.

Privacy PolicyTerms of Use

Tasly Pharmaceutical/Controversies

Tasly Pharmaceutical controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile

  1. 2017FDA clinical trial results for Compound Danshen Dripping Pills spark controversy
  2. 2014Litigation over safety criticism of a Tasly product

  1. 2017

    FDA clinical trial results for Compound Danshen Dripping Pills spark controversy

    In 2017, Li Lianda published an article questioning the results of Tasly's U.S. Phase III clinical trial of Compound Danshen Dripping Pills. The company publicly rebutted this, saying that some statistical indicators were significant, and stated that it would supplement confirmatory trials to meet application requirements. This entry records the controversy over interpretation of the trial results and does not treat the critical article as an FDA negative ruling.

    Source

  2. 2014

    Litigation over safety criticism of a Tasly product

    Pharmacologist Li Lianda criticized the safety of a key Tasly product in 2009. Tasly sued him in 2013, alleging that the criticism was baseless and influenced by financial and employment relationships with Guangzhou Pharmaceutical. In September 2014, the Tianjin High People's Court ruled in Tasly's favor and ordered Li to apologize and pay CNY 300,000 in compensation.

    Source